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T-cell activation by treatment of cancer patients
with EMD 521873 (Selectikine), an IL-2/anti-DNA
fusion protein
Julien Laurent1,3*, Cedric Touvrey1,8, Silke Gillessen2, Magali Joffraud1, Manuela Vicari1, Caroline Bertrand1,
Stefano Ongarello3, Bernd Liedert3, Elisa Gallerani4, Joachim Beck5, Aurelius Omlin2, Cristiana Sessa4,
Sonia Quaratino3, Roger Stupp6, Ulrike S Gnad-Vogt3,9 and Daniel E Speiser7
Abstract
Background: EMD 521873 (Selectikine or NHS-IL2LT) is a fusion protein consisting of modified human IL-2 which
binds specifically to the high-affinity IL-2 receptor, and an antibody specific for both single- and double-stranded
DNA, designed to facilitate the enrichment of IL-2 in tumor tissue.
Methods: An extensive analysis of pharmacodynamic (PD) markers associated with target modulation was assessed
during a first-in-human phase I dose-escalation trial of Selectikine.
Results: Thirty-nine patients with metastatic or locally advanced tumors refractory to standard treatments were
treated with increasing doses of Selectikine, and nine further patients received additional cyclophosphamide. PD
analysis, assessed during the first two treatment cycles, revealed strong activation of both CD4+ and CD8+ T-cells
and only weak NK cell activation. No dose response was observed. As expected, Treg cells responded actively to
Selectikine but remained at lower frequency than effector CD4+ T-cells. Interestingly, patient survival correlated
positively with both high lymphocyte counts and low levels of activated CD8+ T-cells at baseline, the latter of
which was associated with enhanced T-cell responses to the treatment.
Conclusions: The results confirm the selectivity of Selectikine with predominant T-cell and low NK cell activation,
supporting follow-up studies assessing the clinical efficacy of Selectikine for cancer patients.
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Background
T-lymphocytes have the potential to limit tumor progres-
sion but may be impaired in their function due to lack of
growth factors and/or the presence of immunosuppressive
mechanisms, particularly within metastatic lesions [1-3].
Immunotherapy with recombinant human interleukin-2
(IL-2) is an attractive treatment option for certain meta-
static cancers, as it exerts both stimulatory and regulatory
functions on the immune system and is, along with other
members of the common γ chain (γc) cytokine family,
central to immune homeostasis [4,5].
IL-2 acts via IL-2 receptors (IL-2R), consisting of
either the trimeric αβγ receptor, or the dimeric βγ re-
ceptor [6]. Both IL-2R variants transmit signaling upon
IL-2 binding. However, the trimeric αβγ receptor has
10–100 times higher affinity for IL-2 than the dimeric
form [7], because IL-2Rα (CD25) confers high-affinity
binding to IL-2. The trimeric IL-2R is mainly expressed
on activated T-cells and CD4+ Treg cells (forkhead box
P3 [Foxp3] positive T-cells) [7]. High-dose IL-2 is used
for the treatment of patients with metastatic melanoma
and metastatic renal cell carcinoma, and has a long-term
impact on overall survival [8,9]. However, high-dose IL-2
treatment is associated with considerable toxicity, in par-
ticular vascular leak syndrome (VLS) with accumulation
of extravascular fluid in organs such as the lung and
liver. [10-12]. There is no treatment for VLS other than
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withdrawal of IL-2. Low-dose IL-2 regimens have been
tested in patients to reduce side effects, at the price of
reduced therapeutic results [13,14]. Many mechanisms
have been proposed to explain VLS. Toxicity has been
attributed to direct binding of IL-2 to endothelial cells
via a motif resembling a component of bacterial toxins
[15] and centered around aspartic acid residue 20 (D20);
others reported a vasopermeability enhancing fragment of
IL-2 extending from residues 22 to 58 that increases vas-
cular permeability independent of IL-2 bioactivity [10], or
proposed that activation of cells bearing the intermediate-
affinity IL-2 receptor in the vascular compartment leads
to inflammatory cytokine release by natural killer (NK)
and other cells [16]. In order to target IL-2 to tumor in
a way of reducing its potential toxicity, Merck KGaA
(Darmstadt, Germany) developed a novel fully huma-
nized IL-2 fusion protein, EMD521873 or NHS-IL2LT
(Selectikine), for the treatment of solid tumors and B-cell
non-Hodgkin lymphoma [17]. Selectikine comprises the
monoclonal antibody (mAb) NHS76, which recognizes
single-or double-stranded DNA often released from dying
tumor cells either spontaneously or following treatment
with radiation or chemotherapy [18,19], and two gene-
tically modified IL-2 molecules, with a D20T mutation
aimed at eliminating the toxin motif responsible for endo-
thelial cell binding [15]. Pre-clinical data revealed that
Selectikine retained low toxicity and induced anti-tumor
responses. Multiple cycles of treatment can be adminis-
tered safely and with the potential for improved efficacy.
Furthermore, it has been shown that the D20T mutation,
in the context of a whole antibody immunocytokine, was
highly selective for the high-affinity IL-2R [17]. A caveat of
targeting the high-affinity receptor is the possibility of acti-
vating Treg cells. Selectikine was tested in a phase I dose-
escalation first-in-human study in patients with advanced
solid tumors, as a 1-h intravenous (iv) infusion on 3 con-
secutive days every 3 weeks (group 1). Low-dose adminis-
tration of cyclophosphamide at 300 mg/m2 one day
prior to the first Selectikine infusion in each cycle was
also assessed (group 2) as cyclophosphamide has been
reported to suppress Treg cells and to enhance the anti-
tumor activity of immunotherapy [20-23]. At all dose
levels tested, no severe cardiovascular side-effects in-
cluding severe hypotension or vascular leak syndrome,
usually associated with native IL-2, were observed. Also,
no objective tumor responses, but prolonged periods of
disease stabilization in some patients, were observed
[24]. We took the opportunity of this first-in-human
phase I clinical trial to investigate immune modulatory
effects induced by Selectikine. To this aim, an extensive
analysis of pharmacodynamic markers was conducted
during the first two treatment cycles. Here we report the
results of this immune-monitoring, mainly from patients
treated in group I.
Materials and methods
Study design, patient eligibility criteria and clinical data
are detailed in the Additional file 1 available online, and
in the recent paper by Gillessen et al. [24]. The study
was performed in accordance with the guidelines of the
declaration of Helsinki, the International Conference on
harmonization, and regulatory authorities and the
protocol was approved by local ethics committees.
Blood samples
For flow cytometry analysis, whole blood (10 mL) was
collected in EDTA tubes (VacutainerW Blood Collection
Tubes, Becton-Dickinson [BD], Basel, Switzerland) on day
1, before Selectikine infusion (group 1) or before cyclophos-
phamide administration (group 2) and on day 8 during the
first two cycles of treatment, and sent to a central labo-
ratory for direct analysis within 24 h. During the
second cycle, on days 1 and 8 for both patient groups, an
additional 50 mL of blood was collected in Lithium-
Heparin tubes (VacutainerW Blood Collection Tubes, BD)
and PBMC were isolated and frozen locally for further
functional analysis. Briefly, blood was diluted 50%
with PBS, overlayed onto Ficoll-Histopaque 1.077 (Sigma-
Aldrich Chemie Gmbh, Munich, Germany) and centri-
fuged for 30 min at 400 × g and 20°C. The PBMC fraction
was collected, washed in PBS, counted, aliquoted, and fro-
zen at −80°C in 90% FCS/10% DMSO. In addition, 6 mL
of whole blood was collected in Vacutainer SST tubes
(BD) on days 1 and 3 during the first two cycles. Sera were
prepared locally and frozen until analysis. Serum levels of
IL-10, sIL-2R (R&D systems, Minneapolis, USA) and
neopterin (IBL, Hamburg, Germany) were measured by
ELISA according to the manufacturer’s instructions.
Flow cytometry
Fluorescence-activated cell sorting (FACS) analysis
on fresh blood was performed on total leucocytes
after lysis of erythrocytes. Briefly, cells were stained
with the following mAbs: FITC-conjugated anti-Bcl2,
anti-Ki67, anti-perforin; and isotype control IgG1k
or IgG2b; PE-conjugated anti-CD45RA, anti-CD127;
PerCPconjugated anti-CD8, anti-CD3, anti-HLA-DR,
anti-CD56 and anti-CD16; PE-Cy7-conjugated anti-
CD25, anti-CCR7; APC-conjugated anti-CD38, anti-
HLA-DR, anti-granzyme B, and isotype control IgG1k;
APC-H7-conjugated anti-CD4 and anti-CD3. Anti-
bodies were purchased from BD Pharmingen, except
for FITC-conjugated anti-Foxp3 which was purchased
from eBiosciences, San Diego, USA. Data were
acquired using a FACS LSRII flow cytometry machine
(BD), and analyzed with FCSExpress version 3 software
(De Novo software, Ontario, Canada).
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Peptide stimulation assay
Antigen-specific CD8+ T-cell responses specific for
cancer-testis tumor antigens were assessed in vitro by
stimulating PBMCs collected on days 1 and 8 of the
second cycle of Selectikine treatment with five different
HLA-A2 restricted peptides (Melan-A/ELAGIGILTV;
MAGE-A3/KVAELVHFL; NY-ESO-1/SLLMWITQA; MAGE-
A10/GLYDGMEHL and SSX-2/KASEKIFYV). Briefly, CD8+
T-cells (1 × 105) enriched by magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany) were co-cultured
with irradiated CD8- cells (ratio of 1:1) in RPMI plus 8%
AB human serum (Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) in 96-well plates, and stimulated
with the peptides (20 μM). After 48 h, medium was sup-
plemented with IL-2 (150 U/mL) and IL-7 (20 ng/m).
On day 7, cells were collected, stained with multimers
and antibodies, and analyzed on an LSRII flow cytometer
(BD). Acquired data were analyzed using FCSExpress ver-
sion 3 software (De Novo software).
Intracellular cytokine staining
Intracellular cytokine staining for IFNγ and TNFα was
performed together with labeling with tetramers and
CD8-specific antibodies. 1 × 106 CD8+ enriched T-cells
(Miltenyi Biotec) were incubated for 5 hours at 37°C
with 1 × 106 T2 cells pulsed with 10 μg/mL irrelevant
HIV-1 Pol476–484 (ILKEPVHGV) peptide, or 10 μg/mL
tumor antigenic peptides, or 1 μg/mL PMA/0.25 μg/mL
ionomycin. After 1 h, 10 μg/mL brefeldin A (Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland) was added.
4 h later cells were stained with multimers and anti-
bodies, fixed, permeabilized, and incubated with anti-
IFNγ-FITC and anti-TNFα-APC mAbs in PBS/0.1%
saponin for 30 min at 4°C. Cells were analyzed on a
LSRII flow cytometer (BD). Acquired data were ana-
lyzed using FCSExpress version 3 software (De Novo
software).
Treg cell inhibition test
To test the suppressive activity of Treg cells, their abil-
ity to inhibit the proliferation of autologous CD4+ T-
cells we measured in CFSE assays. Briefly, CD4+ T-cells
were negatively selected using magnetic beads from
PBMC collected on days 1 and 8 of the second cycle of
treatment. The CD25-expressing CD4+ fraction was
then positively selected using the CD4+CD25+ regula-
tory T-cell isolation kit (Miltenyi Biotec) according to
the manufacturer’s instructions. CD4+CD25- T-effector
cells (6 × 105) were labeled with CFSE (final concentra-
tion 2 μM) and cultured in 96 well-plates, stimulated
with anti-CD3 and anti-CD28 beads (DynabeadsW
Human T-Activator CD3/CD28, LuBioScience GmbH,
Lucerne, Switzerland). CD4+CD25+ non-labeled Treg
cells (3 × 105) were added to the cultures (ratio of 1:2).
After 4 days, cells were collected, and stained with the
apoptotic marker VIVID, and anti-CD4 and anti-CD3
mAbs. CFSE intensity was measured on a FACS LSRII
(BD).
Immunohistochemistry
Tumor tissues from archival material (pretreatment) and a
biopsy collected after two treatment cycles were analyzed
by immunohistochemistry. Four-micrometer thick serial
sections of formalin-fixed, paraffin-embedded tissue sam-
ples were prepared. Antigen retrieval carried out using
microwave treatment in 0.1 M sodium citrate, pH 6.0.
Staining was performed with anti-CD8, anti-CD4, anti-
Foxp3 and anti-Ki67 mAbs. Detection was with the
DAKO EnVisionTM + system using diaminobenzidine
(DAB) as the chromogen (DAKO, Trappes, France). Non-
immune mouse IgG was used as a negative control. In
parallel, tissue samples were stained with hematoxylin/
eosin.
Statistical analyses
Values are expressed as mean ± 95% confidence inter-
vals. Statistical analysis was aimed at discovering differ-
ences due to the treatment, both in time and by dose
level. Leukocyte subsets were compared between day 1
and 8 of the first two cycles using repeated measure-
ments mixed model analysis of variance (ANOVA). The
F-test, α = 0.05, in the ANOVA was used to test the
fixed effects, and a post-hoc test (Tukey HSD) was ap-
plied for the pairwise comparisons. Differences were
considered statistically significant at *P < 0.05 (**P ≤ 0.01,
***P ≤ 0.005). All analyses were performed using JMP
v.8.0.2. software (SAS Institute Inc., Cary, US).
Kaplan Meier survival analysis
Survival analyses were performed from the first day of
study treatment to the date of progression, or date of
death, or censored at the date of last observation. Kaplan
Meier (KM) analyses were performed to estimate the
relationships between survival time and biomarker base-
line levels. For each biomarker individually, the baseline
value for every patient was categorized into LOW or
HIGH categories according to levels that were less or
equal to the 33th percentile, or greater than the 66th
percentile. The analysis was performed by the Unit for
Bioinformatics (Merck Serono, Geneva), using the stan-
dard model: Overall Survival Time * Censoring. A log-
rank test was performed to compare the two groups
(LOW, HIGH). Kaplan Meier survival analysis was per-
formed using JMP v.8.0.2. software (SAS Institute Inc.,
Cary, US).
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Results
Clinical background
A total of 48 patients were enrolled, 39 were treated
with Selectikine alone (group 1) in a 3 + 3 dose-
escalation design starting from 0.075 mg/kg through
0.15, 0.225, 0.3, 0.45, 0.6 and finally 0.9 mg/kg; and nine
patients with Selectikine plus cyclophosphamide (group
2, dose levels 0.45 mg/kg and 0.6 mg/kg). Skin rash at a
dose of 0.9 mg/kg was the dose limiting toxicity, and the
maximum tolerated dose was therefore determined as
0.6 mg/kg in group 1. The Selectikine treatment was
associated with typical IL-2-like biological effects includ-
ing lymphopenia followed by lymphocytosis and eosino-
philia at all dose levels, while IL-2 related clinical AEs
were mainly mild to moderate. The skin rash responded
well to topical corticosteroids. Compared to previous
studies, with intermediate to high IL-2 doses, Selectikine
induced only mild hypotension and no vascular leak syn-
drome suggesting improved tolerability of this modified
and more selective IL-2 moiety. Detailed clinical results
have been reported in a recent publication [24].
In the following sections, we focus on the analysis of
pharmacodynamic markers, mainly assessed during the
first two treatment cycles; on day 1 before Selectikine in-
fusion (day −1 for group 2), and on day 8.
Leukocytes
Absolute counts of leukocyte populations in peripheral
blood (clinical laboratory data), including lymphocytes,
monocytes and neutrophils were measured for each
cycle of treatment at the following time points: before
the start of Selectikine infusion (day 1), on day 3 and
day 8. Leukocytes were analyzed for the dose groups
from 0.075 to 0.9 mg/kg Selectikine until treatment dis-
continuation. The data revealed lymphopenia at day 3 at
all doses tested, followed by lymphocytosis (absolute leu-
kocytes count) 8 days after Selectikine administration,
with return to basal levels after each cycle (Figure 1,
upper graph). Lymphocytes were most sensitive to Selec-
tikine, with a systematic and steady increase between
each cycle; whereas the responses of monocytes and
neutrophils were less strong (Figure 1, lower graphs).
Notably, no significant dose effects were observed be-
tween patients subgroups, therefore the data from the
subgroups were pooled for the remaining analyses.
CD4+ and CD8+ T-cells
As lymphocytes responded strongly to treatment, CD8+
and CD4+ T-cells were next analyzed during the first
two treatment cycles. As expected, a statistically signifi-
cant and transitory increase in absolute counts as well as
in the frequency of both CD8+ and CD4+ T-cells was
observed on day 8 after Selectikine infusion (Figure 2A).
Notably, there was a greater increase in CD4+ T-cells on
day 8 of both cycles (2.3-fold increase) compared with
CD8+ T-cells (1.5-fold increase for cycles 1 and 2), lea-
ding to a relatively small but statistically significant
increase of the CD4+/CD8+ ratio after both cycles of
treatment (Figure 2B). As expected, serum concentra-
tions of soluble IL-2R (sIL-2R) were also strongly
increased shortly after Selectikine infusion (Figure 2C).
The analysis of NK cells based on CD56 and CD16 sur-
face markers showed no significant changes for both
Figure 1 Kinetics of subpopulations of leukocytes in patients
treated with Selectikine. Absolute counts (109 cells/L) of total
leukocytes, lymphocytes, monocytes and neutrophils from patients
treated at increasing doses of Selectikine (0.075, 0.15, 0.225, 0.3, 0.45,
0.6 and 0.9 mg/kg). Geometric mean values of absolute counts are
shown for each dose-group, until discontinuation. Blood was drawn
during each treatment cycle at the following time points: day 1
before start of Selectikine infusion and on day 3 and day 8 after start
of Selectikine infusion. Black boxes on the x-axis represent the
treatment, i.e. the 1-h iv infusions of Selectikine during three
consecutive days per cycle.
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cycles monitored in terms of frequency or cytotoxicity
(Additional file 1: Figure S1A and S1B), only a slight in-
crease in absolute numbers was noted during the first
cycle (Additional file 1: Figure S1A). No dose effects
were observed in the analysis of NK cells.
T-cell activation and proliferation
As CD8+ and CD4+ T-cells were both sensitive to Selec-
tikine, the lymphocyte functions were next investigated.
Combinations of Ki67- and HLA-DR-specific antibodies
were used to analyze proliferation, and CD38- and Bcl2-
specific antibodies for activation [25-27]. Strong prolif-
eration was induced in both CD4+ and CD8+ T-cells
after each treatment cycle, reaching a mean of approxi-
mately 20% of proliferative CD4+ T-cells in cycle 1
(23.1% ± 11.4) and 2 (19.0% ± 9.2). The proliferation of
CD8+ T-cells was similar (22.2% ± 15.8) in the first cycle,
but less in the second cycle (10.7% ± 12.4) (Figure 3A).
Proliferating (HLA-DR+ Ki67+) cells were predominantly
effector memory (EM) cells, as identified by the absence
of CCR7 and CD45RA expression (Figure 3A dot plot,
Additional file 1: Figure S2A). Similar to the proliferation
state, activated cells (CD38+ Bcl-2-) were also increased
after both cycles for CD4+ and CD8+ T-cells, with a
decrease of the activation state of CD8+ T-cells during
the second treatment cycle (Figure 3B). As expected,
activated cells were primarily EM cells (Figure 3B dot
plot, Additional file 1: Figure S2B). In accordance
with these observations, the absolute count of EM
CD4+ T-cells was increased during both cycles (Additional
file 1: Figure S2C), whereas the absolute count of EM
CD8+ T-cells only increased during the first cycle
(Figure 3C). CD8+ effector cell properties were not found
to be altered by Selectikine treatment, as indicated by
ex vivo assessment of intracellular expression of granzyme
B and perforin (Figure 3D), and the production of IFNγ
and TNFα after a 4-h stimulation with PMA/ionomycin
(Figure 3E). Finally, neopterin levels were increased,
reflecting the overall activation of the cellular immune
system (Additional file 1: Figure S2D).
CD4+ Treg
CD4+ Treg cells are inhibitory immune cells, character-
ized by high expression of Foxp3 and CD25. Besides
CD25, Treg cells also express the remaining chains of
the high-affinity IL-2 receptor, and are thus sensitive to
IL-2 and Selectikine, similar to conventionally activated
T-cells. As expected, the frequency of Treg cells was
considerably increased after each treatment cycle, rea-
ching a mean of approximately 25% of CD4+ T-cells
(cycle 1, 24.5% ±11.3; cycle 2, 23.8% ±1.6) (Figure 4A).
These Treg cells were CD3+ CD4+ CD25+ Foxp3+ and
CD127- (Figure 4A, dot plot); CD127 expression being
mainly expressed on subpopulations of CD4+ non-Treg
cells and CD8+ T-cells (Additional file 1: Figure S3A). Of
note, a decrease in CD127 expression was observed on
CD4+ T-cells but not on CD8+ T-cells. The strong sensi-
tivity to Selectikine of Treg cells was confirmed by abso-
lute counts, with 20 ± 60 and 11 ± 7-fold increase in
cycles 1 and 2, respectively (day 8); while CD4+ non-
Treg cells increased by 1.6 ± 5 and 1.5 ± 0.5-fold, respect-
ively, similarly to CD8+ T-cells. This means that the
CD4+/CD8+ ratio remained unchanged when excluding
Treg cells (Figure 4B and Additional file 1: Figure S3B).
Of note, a single injection of low-dose cyclophospha-
mide (group 2) did not affect their frequency (Additional
file 1: Figure S3C). The inhibitory function of Treg cells
at baseline (day 1) and on day 8 of the second treatment
cycle was also measured in eight randomly selected
Figure 2 Effects of Selectikine treatment on peripheral CD4+
and CD8+ T-cells. (A) Absolute counts (cells/mm3) and frequencies
(%) of CD3+CD4+ and CD3+CD8+ T-cells (gated on lymphocytes
using FSC/SSC parameters) on days 1 and 8 during the first and
second treatment cycles. Graphs show the individual values of 39
patients treated with 0.075 to 0.9 mg/kg Selectikine alone. Bars
represent geometric mean values, with 95% CI. (B) CD4+/CD8+ ratios
on days 1 and 8 during the first and second treatment cycles.
Box-and-whiskers graphs show geometric mean with 95% CI.
(C) Serum concentrations (ng/mL) of soluble interleukin-2 receptor
on days 1 and 3 during the first and second treatment cycle. The
box and whisker graph shows geometric mean values per dose-
group. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.005.
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patients from group 1 (Additional file 1: Figure S3D). In
five of these patients, Treg cells inhibited CD4+ T-cell
proliferation between 60 and 100% (ratio 1:2) to a simi-
lar extent on days 1 and 8. In the three remaining
patients, Treg cells were not inhibitory on either day
(Table 1). The increase of Treg cell frequency without
changes of their inhibitory function may reflect early
production of IL-10, as detected in sera on day 3 after
the first dose of Selectikine (Figure 4C). Finally, analysis
of Ki67 expression revealed that a mean of approximately
50% of Treg cells were proliferating cells on day 8 (cycle 1,
51.6% ±11.6; cycle 2, 46.7% ±15.8) (Additional file 1:
Figure S3E).
In situ analysis
We further investigated whether lymphocytes accumulated
in situ, by studying a post-treatment biopsy collected after
the second cycle, from a patient with metastatic melanoma
treated with 0.225 mg/kg of Selectikine and matched arch-
ival material collected shortly prior to start of Selectikine
Figure 3 Functional analysis of CD4+ and CD8+ T-cells before and after treatment with Selectikine. (A) Frequencies (%) of proliferative
CD4+ and CD8+ T-cells (Ki67+ HLA-DR+) on days 1 and 8 during the first and second treatment cycles. Dot plots represent HLA-DR versus Ki67
staining of CD8+ gated T-cells on days 1 and 8 during the first treatment cycle. The right dot plot shows expression of CCR7 and CD45RA of cells
from gate (1), on day 8 of the first cycle. (B) Frequencies (%) of activated cells (CD38+ Bcl2-) within CD4+ and CD8+ T-cells on days 1 and 8 during
the first and second treatment cycle. Dot plots represent CD38 versus Bcl2 staining in CD8+ gated cells on days 1 and 8 during the first treatment
cycle. The right dot plot represents CCR7 versus CD45RA repartition of activated CD8+ T-cells (1) on day 8 of the first cycle. (C) Absolute counts
(cells/mm3) of effector memory (EM) CD8+ T-cells (CCR7- CD45RA-) on days 1 and 8 during the first and second treatment cycles. Graphs show
individual values of 39 treated patients. Bars represent geometric mean values with 95% CI. (D) Frequency of GrB+ perforin+ cells in CD8+ gated
cells on days 1 and 8 during the first and second treatment cycles. The box-and-whiskers graph shows geometric mean with 95% CI. (E)
Expression of IFNγ and TNFα (%) in CD8+ T-cells on days 1 and 8 of the second cycle, after a 4-hour in vitro stimulation with PMA/ionomycin. Dot
plot representation of IFNγ versus TNFα staining in CD8+ gated T-cells after in vitro stimulation. Box-and-whiskers graphs show geometric mean
with 95% CI from 9 randomized patients treated with 0.075 to 0.9 mg/kg Selectikine alone. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.005.
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treatment. Interestingly immunohistochemistry staining
revealed significantly increased expression of Ki67 by lym-
phocytes after Selectikine treatment compared with the
pretreatment sample. Furthermore, there was an increased
infiltration of CD8+ T-cells, while CD4+ and Foxp3+ Treg
cells were unchanged (Figure 4D). Notably, post-therapy
immune response in this patient was similar to other trea-
ted patients, with increased counts of CD8+, CD4+ and
Treg cells, and strong activation and proliferation of T-cells
(individual data not shown).
Tumor-antigen specific CD8+ T-cells
We investigated whether Selectikine treatment promoted
responses of tumor-antigen specific CD8+ T-cells. Of eight
randomly selected HLA-A2 positive patients, CD8+ T-
cells were isolated at baseline and on day 8 after
Figure 4 Effects of Selectikine on regulatory CD4+ T-cells. (A) Frequency (%) of CD4+ Treg cells based on Foxp3 and CD25 expression. Dot
plot representations of Foxp3 versus CD25 staining on days 1 and 8 during the first treatment cycle; and Foxp3 versus CD127 on day 8. Graphs
represent individual values of 39 treated patients. Bars represent the geometric mean with 95% CI. (B) Absolute counts (Cells/mm3) of Treg cells
(Foxp3+CD25+CD4+CD3+) and CD4+ non-Treg cells (Foxp3-CD25-CD4+CD3+) on days 1 and 8 during the first and second treatment cycles.
Box-and-whiskers graphs show geometric mean with 95% CI. (C) Serum concentrations (pg/mL) of IL-10 measured on days 1 and 3 after
Selectikine infusion in 39 treated patients in patient group 1. (D) Ki67, CD8+, CD4+ and Foxp3 immunoperoxydase staining in tumor tissue before
the study (PRE-treatment), and after the second treatment cycle (POST-treatment) from melanoma patient N° 101 1102 treated with 0.225 mg/kg
Selectikine. **P ≤ 0.01, ***P ≤ 0.005.
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Selectikine infusion during the second cycle, and stimu-
lated with a panel of peptides representing cancer-testis
antigenic epitopes from the tumor antigens Melan-A,
MAGE-A3, MAGE-A10, NY-ESO-1 and SSX-2. After one
week of peptide stimulation, cells were isolated and
stained with tetramers combined with intracellular stain-
ing for IFNγ and TNFα. Lymphocytes obtained from day
8 (second treatment cycle) did not show significant
enrichment of tumor-antigen specific T-cells compared
with those from day 1 (Additional file 1: Figure S4A). One
patient showed strong activation of Melan-A specific T-
cells at the baseline of the second cycle, but without a
further increase on day 8 (Additional file 1: Figure S4B).
Measurements of IFNγ and TNFα production within
tetramer positive CD8+ T-cells showed no functional en-
hancement after Selectikine treatment (Additional file 1:
Figure S4C), which was similar to our findings for whole
circulating CD8+ T-cells (Figure 3E).
Correlation with patient survival
Preliminary evidence of clinical efficacy was investigated.
No tumor responses were recorded, but prolonged disease
stabilization in some of these heavily pre-treated patients
observed. Median overall survival was 9.6 months [95% CI
5.6–16.4] in group 1, and 7.0 months [95% CI 4.3–23.2] in
group 2. Previously reported [28-30], associations between
patient survival and lymphocyte properties (as described
in Figures 1 and 2), were further examined. Interestingly,
high lymphocyte counts at baseline were significantly
associated with longer survival (Figure 5A). Furthermore
low levels of activated CD8+ T-cells (CD38+Bcl2-%) at
baseline were associated with longer patient survival
(Figure 5B), while the absolute count was not (Figure 5C).
Notably, the highest increase of CD8+ T-cell activation at
day 8 was observed in patients who presented low activa-
tion levels before the start of treatment (Additional file 1:
Figure S5A), and was thus independent of lymphocyte
counts (Additional file 1: Figure S5B). Therefore, treatment
induced T-cell activation appeared to occur preferentially
in patients with low-level activation at baseline and seemed
to be associated with improved clinical outcome in this
small number of patients. Of note, Treg cells did not impact
on overall survival (Additional file 1: Figure S5C).
Discussion
IL-2 therapy can be effective in the treatment of patients
with metastatic renal cell carcinoma and metastatic
melanoma [31]. Clinical responses to high-dose IL-2
therapy occur in 15% to 20% of patients. However, side-
effects are frequent and can be serious [32,33]. More
targeted IL-2 therapies are necessary to improve safety
and efficacy [34]. Several small phase II studies recorded
some clinical responses with the administration of lower
doses of IL-2 but no cases of long lasting responses were
reported [35]. A randomized study comparing high- and
low-dose IL-2 in 156 patients with metastatic renal
cancer by Yang et al. [14], supported the finding that
low-dose IL-2 regimens can cause the regression of
advanced renal cell cancer. However, the higher dose of
IL-2 appeared to produce greater biological activity, to-
gether with a higher clinical response rate.
The novel recombinant IL-2/anti-DNA fusion protein,
Selectikine, was developed with the aim of maximizing
immunomodulatory action and clinical efficacy at min-
imal vascular toxicity, despite treatment at optimal doses
[36]. Our analysis of peripheral leukocytes showed a
strong and transitory increase early after infusion of
Selectikine. As expected, lymphocytes responded readily
while the effects on monocytes were less pronounced,
and no significant changes were observed to neutrophils
(Figure 1). Strong increases in both percentages and ab-
solute counts were observed for both CD4+ and CD8+
T-cells (Figure 2), while only weak effects were found for
NK cells (Additional file 1: Figure S1), confirming the se-
lectivity of Selectikine for T-cells compared with native
IL-2 and an immunocytokine comprising wild-type IL-2
[37]. Furthermore, major biological effects included a
significant increase in the soluble factors sIL-2R, neop-
terin and IL-10 [38]. Recently, treatment with EMD
273063, a humanized anti-GD2 mAb fused to native IL-
2, showed no significant effects on peripheral CD4+ and
CD8+ T-cells 10 days after infusion of the molecule [38].
Nevertheless, EMD 273063 administration resulted in
increased levels of the soluble factors sIL-2R, neopterin
and IL10, as reported in the present study.
Strong activation and proliferation of lymphocytes was
observed, essentially of EM T-cells (Figure 3 and Additional
file 1: Figure S2), even at the lowest dose (0.075 mg/kg) of
Selectikine. In general, a dose effect on biological responses
was not found. This was remarkable, since strong immune
Table 1 Treg inhibition capacity
Inhibition of CD4+ proliferation by Tregs
Dose Patient Inhibition (%)
Day 1 Day 8
0.075 103 1301 99 88
0.075 103 1318 75 48
0.075 102 1213 68 49
0.3 103 1303 97 92
0.3 103 1309 0 0
0.6 103 1310 82 77
0.6 103 1314 0 2
0.6 101 1104 0 0
Capacity of inhibition (%) of CD4+ T-cell proliferation induced by CD3+/CD28+
stimulation by Treg cells, sorted on days 1 and 8 during the second treatment
cycle. Samples from 8 randomized patients treated at 0.075, 0.3 and 0.6 mg/kg
Selectikine alone were tested.
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stimulation even at low doses of Selectikine, without major
toxicity was demonstrated. In the field of IL-2 therapy,
these biologic effects are considered as potentially benefi-
cial. They are mostly observed at high doses with wild-type
IL-2 and are thus associated with toxicity [39]. The absence
of a dose effect in the present study should be interpreted
with caution due to the heterogeneity of the patient popula-
tion comprising different types of cancers with different
pretreatment regimens. To reliably investigate a dose effect,
a randomized study investigating different doses in a more
homogeneous population would be necessary.
As expected, Treg cells responded actively, with increased
frequencies and absolute counts after infusion of Selectikine
(Figure 4A, B). However, their inhibitory capacities were
unchanged (Table 1), based on the same cell ratio. The in-
crease of Treg number is far more important than the
Figure 5 Pharmacodynamic markers correlative evaluation with patient survival. (A) Kaplan-Meier Survival Curve with 95% confidence
limits stratified by lymphocyte counts (cell/mm3) at baseline in patient groups 1 and 2. (B) Kaplan-Meier Survival Curve with 95% confidence
limits stratified by percent of activated CD8+ T-cells (CD38+bcl2-,%) at baseline in patient groups 1 and 2. (C) Kaplan-Meier Survival Curve with
95% confidence limits stratified by absolute count of activated CD8+ T-cells (CD38+bcl2-, Cell/mm3) at baseline in patient groups 1 and 2.
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increase of other T-cell populations, which could reflect a
change in effector/regulatory T-cell ratio in vivo. Similarly
to effector cells, Selectikine effects were transitory. Further-
more, increased Treg cell frequency appeared to be due
to the proliferation of pre-existing Treg cells, as they
expressed Ki67 (Additional file 1: Figure S3). The elevated
levels of IL-10 may be a direct consequence of Treg cell
sensitivity to the therapy (Figure 4C). Additional treatment
with low dose cyclophosphamide prior to Selectikine infu-
sion did not inhibit Treg cells (Additional file 1: Figure
S3C), which is compatible with the majority of other studies
[40]. The usefulness of cyclophosphamide for therapeutic
inhibition of Treg cells remains questionable [41,42]. Im-
portantly, in addition to Treg cells, the levels of CD4+
effector T-cells were also increased after the infusion of
Selectikine (Figure 4B). Furthermore, CD8+ effector T-cells
were also activated and increased in numbers and frequen-
cies. Thus, even if Treg cells were highly sensitive to Selec-
tikine, T-cell activation was broad, with increased activity of
both effector and regulatory T-cells, in contrast to recent
studies of low dose IL-2 treatment demonstrating preferen-
tial and sustained activation of Treg cells [43,44]. The fact
that Selectikine targets the tumor tissue through the bind-
ing of free DNA may result in a different T-cell activation
in the tissue compared to periphery, which could perhaps
also be the case for Treg cells as suggested by the analysis
of the single post-therapy biopsy (Figure 4D). For this pa-
tient, the in situ analysis revealed different effects in the
tumor compared to the periphery. This aspect should be
addressed in future clinical trials.
Recently, Levin et al. have published the first results
evaluating a new class of IL-2 named a superkine, which
has been engineered to eliminate the functional require-
ment of CD25 expression [45]. In vitro and in vivo expe-
riments revealed that the new IL-2 superkine induced
superior expansion of cytotoxic T-cells compared to Treg
cells, leading to improved antitumor responses and reduced
pulmonary edema. Compared with the observations made
with Selectikine, it will be interesting to evaluate both mole-
cules in terms of immunological responses, toxicity and
VLS when the IL-2 superkine reaches the clinic.
PBMC available from before and after the second treat-
ment cycle were studied to investigate whether Selectikine
treatment had detectable effects on tumor antigen-specific
CD8+ T-cells. Several patients presented detectable levels
of tumor-specific T-cells, and one patient developed a
strong response. However, in most patients there was no
increase in the frequency or the functionality of tumor-
specific T-cells (Additional file 1: Figure S4). Even though
many of these T-cells may have been induced by the
treatment, in the absence of the assessment of pretreat-
ment samples, this could not be formally addressed in
this study. Unfortunately, it was also not possible to deter-
mine patient tumor antigen expression, which made it
impossible to exclude those T-cells with specificities for
non-expressed antigens (i.e. the majority) from the ana-
lysis. As a first-in-human study of Selectikine, at the time
of the study design, these factors were not of high priority.
In cancer patients, tumor-infiltrating lymphocyte counts
and localization are often independent prognostic factors
for survival [46-50]. However, several studies including
our own (Figure 5A) showed also that the counts of circu-
lating lymphocytes correlated positively with survival
[28-30]. Notably, in our study enhanced pre-activation of
CD8+ T-cells at baseline correlated with short survival
(Figure 5B), while no correlation was observed when
considering Treg cells (Additional file 1: Figure S5C).
However, these are preliminary observations since the
phase I study design and the low patient number do not
allow for definitive conclusions on clinical outcome. Lar-
ger studies are required to address these questions, and to
test whether low-level T-cell activation at baseline, and
strong therapy induced T-cell activation are predictive for
favourable clinical outcome.
Conclusion
This first-in-human trial with Selectikine, a novel immu-
nocytokine IL-2/anti-DNA fusion protein, confirms its
selective biologic activity. Larger studies are now required
to confirm our findings, and to determine potential clin-
ical benefits. Finally, further analyses of post-treatment
biopsies will provide more detailed insights into the
biological effects of the dual targeting (IL-2R/DNA) by
Selectikine.
Additional file
Additional file 1: Materials and methods.
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